Your browser doesn't support javascript.
loading
Current advances in prognostic and diagnostic biomarkers for solid cancers: Detection techniques and future challenges.
Pal, Mintu; Muinao, Thingreila; Boruah, Hari Prasanna Deka; Mahindroo, Neeraj.
Afiliación
  • Pal M; School of Health Sciences, University of Petroleum and Energy Studies (UPES), Energy Acres, P.O. Bidholi, Via-Prem Nagar, Dehradun 248007, Uttarakhand, India; Department of Pharmacology, AIIMS, Bathinda 151001, Punjab, India. Electronic address: mpal24@yahoo.com.
  • Muinao T; Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology (NEIST), Jorhat 785006, Assam, India; Academy of Scientific & Innovative Research (AcSIR), CSIR-NEIST Campus, Jorhat 785006, Assam, India.
  • Boruah HPD; Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology (NEIST), Jorhat 785006, Assam, India; Academy of Scientific & Innovative Research (AcSIR), CSIR-NEIST Campus, Jorhat 785006, Assam, India; Government Model College, Kaziranga, Go
  • Mahindroo N; School of Health Sciences, University of Petroleum and Energy Studies (UPES), Energy Acres, P.O. Bidholi, Via-Prem Nagar, Dehradun 248007, Uttarakhand, India.
Biomed Pharmacother ; 146: 112488, 2022 Feb.
Article en En | MEDLINE | ID: mdl-34894516
Solid cancers are one of the leading causes of cancer related deaths, characterized by rapid growth of tumour, and local and distant metastases. Current advances on multimodality care have substantially improved local control and metastasis-free survival of patients by resection of primary tumour. The major concern in disease prognosis is the timely detection of resectable or metastatic tumour, thus reinforcing the need for identification of biomarkers for premalignant lesions of solid cancer. This ultimately improves the outcome for the patients. Therefore, the purpose of this review is to update the recent advancements on prognostic and diagnostic biomarkers to enhance early detection of common solid cancers including, breast, lung, colorectal, prostate and stomach cancer. We also provide an insight into Food and Drug Administration (FDA)-approved solid cancers biomarkers; various conventional techniques used for detection of prognostic and diagnostic biomarkers and discuss approaches to turn challenges in this field into opportunities.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Biomed Pharmacother Año: 2022 Tipo del documento: Article Pais de publicación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Biomarcadores de Tumor / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies / Screening_studies Límite: Humans Idioma: En Revista: Biomed Pharmacother Año: 2022 Tipo del documento: Article Pais de publicación: Francia